The FDA launched a pilot program designed to speed up Phase I initiation by pairing drug sponsors with prequalified research institutions. Under the initiative, sponsors and selected sites can file expedited IND application components on a rolling basis during the pre-IND phase, with parallel workstreams such as Institutional Review Board assessment and site activation. The agency said the program aims to reduce delays between IND preparation and first-in-human study start, using the QRIs’ specialized scientific expertise to support faster FDA review and acceptance of individual components. Applications are accepted until October 30, with the FDA planning to select eight to ten projects. For biotech operators, the program is a concrete attempt to professionalize and compress early development execution, particularly for sponsors that want to accelerate clinical timelines without sacrificing regulatory quality. It also signals the FDA is collecting operational evidence to inform future modernization of early-stage clinical support.